Events

Save the date for an in-person Investor Day with Valneva, discussing the Company’s current vaccine pipeline, commercial products and future directions. The event will highlight Valneva’s core near- and mid-term value drivers: its BLA-stage chikungunya virus (CHIKV) vaccine candidate, including pre-commercial preparations and market access activities, and its Phase 3 Lyme disease vaccine candidate (Partner:…

Join us monthly for our Biotech Capital Markets update featuring an interactive and informative discussion on the current state of the biotechnology markets, incorporating relevant insights on the financing environment in the healthcare sector. Attendees will have the opportunity to ask questions live. It is important to note the monthly call will only be available during the scheduled…

Join us for a Fireside Chat featuring Professor Richard Lafayette, MD (Stanford University Medical Center), who will discuss the evolving treatment landscape and unmet medical needs of patients suffering from IgA nephropathy (IgAN). The Calliditas Therapeutics leadership team will also provide a brief summary of the data from the Part A of the NefIgArd Phase 3…

Join us for a KOL Event with Mendus, featuring Amer Zeidan, MBBS, MHS (Yale School of Medicine) and Uwe Platzbecker, MD (University Hospital in Leipzig) who will discuss the current treatment landscape in acute myeloid leukemia (AML), and the emergence of maintenance therapy as a new paradigm for treatment of AML patients in remission. The discussion will set the…

Join us for an Investor Event with TScan Therapeutics on the Company’s clinical plans to treat a variety of solid tumors with multiplexed TCR-T cell therapy. Harnessing ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, TScan looks to provide customized multiplexed therapies unique to each…

This content is password protected. To view it please enter your password below: Password: The post Protected: Ideaya BioSciences Synthetic Lethality Investor Day appeared first on LifeSci Events.

Antengene to host 2022 R&D Day English session on November 15 to provide an in-depth presentation of its development pipeline and key research. The post Antengene R&D Day: Treating Patients Beyond Borders appeared first on LifeSci Events.

Join us for a discussion with immunotherapy expert Michael Aaron Morse, MD (Duke University School of Medicine), who will provide an overview of the oncolytic virus landscape and the encouraging data that positions Theriva Biologics’ novel oncolytic adenovirus (OV) platform at the forefront of development to address devastating cancers with high unmet need. The discussion will also…

Join us for a KOL Event with OKYO Pharma, featuring Pedram Hamrah, MD (Tufts University School of Medicine) who will discuss the current treatment landscape for patients suffering from Dry Eye Disease (DED) and the potential of OKYO’s OK-101 drug candidate for treating patients with this chronic disease. OKYO Pharma’s leadership team will provide a company update…

Join us for a virtual key opinion leader (KOL) event with Oncolytics Biotech, featuring Dirk Arnold, MD, PhD (Asklepios Tumorzentrum Hamburg), Andrea Bullock, MD, MPH (Beth Israel Deaconess Medical Center) and Thomas Seufferlein, MD, PhD (Ulm University, Germany). During the event, the KOLs and members of the Oncolytics management team will discuss the current treatment landscape…